ImmuPharma plc (LON:IMM – Get Free Report) shares fell 15.4% on Friday. The stock traded as low as GBX 3.10 and last traded at GBX 3.30. 2,780,993 shares were traded during mid-day trading, an increase of 13% from the average session volume of 2,458,482 shares. The stock had previously closed at GBX 3.90.
ImmuPharma Price Performance
The firm has a market capitalization of £20.04 million, a PE ratio of -3.86 and a beta of 3.02. The company’s fifty day simple moving average is GBX 3.66 and its 200 day simple moving average is GBX 4.77.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. On average, analysts anticipate that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
